Fast Five Quiz: Exudative (Wet) Age-Related Macular Degeneration Management

F. Ryan Prall, MD


November 05, 2020

Long-term studies have shown that, on average, patients eventually lose best-corrected visual acuity. The HORIZON extension study documented adverse events and visual acuity results in patients treated with a VEGF inhibitor over 4 or more years. Rates of adverse events, including stroke and myocardial infarction, continued to be low with long-term treatment. Some visual acuity gains achieved with monthly treatment during the initial phases of the studies were lost as patients were followed and treated less frequently during the latter years of the HORIZON study.

Learn more about treatment of wet AMD with VEGF inhibitors.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.